Actinium Strengthens Executive Team and Enhances Clinical Development Capabilities with the Appointment of Dr. Mark Berger as Chief Medical Officer
18 janv. 2017 08h00 HE
|
Actinium Pharmaceuticals
Dr. Berger brings 20 years of drug development experience highlighted by the FDA approvals of Mylotarg® for acute myeloid leukemia, the only drug approved in AML in several decades, and Tykerb® for...
Actinium Pharmaceuticals to Present at 9th Annual Biotech Showcase™ 2017 Conference
10 janv. 2017 07h00 HE
|
Actinium Pharmaceuticals
NEW YORK, Jan. 10, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...
Actinium Pharmaceuticals to Present at 9th Annual Biotech Showcase™ 2017 Conference
04 janv. 2017 07h00 HE
|
Actinium Pharmaceuticals
NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...
Actinium Pharmaceuticals Appoints Jeannine Larrieux, Ph.D. as Director of Analytical Development to Support BLA and IND Enabling Analytical Studies for Current and Future Clinical Programs
19 déc. 2016 07h00 HE
|
Actinium Pharmaceuticals
- Dr. Larrieux brings significant experience managing analytical development quality control of immunotherapies to treat cancer and small molecule therapies at pharmaceutical and biotechnology...
Actinium Pharmaceuticals Announces Submission of EU Orphan Designation Application for Actimab-A
13 déc. 2016 07h00 HE
|
Actinium Pharmaceuticals
- Actimab-A has received Orphan Drug Designation in the U.S. - Orphan Designation in the EU can result in regulatory assistance, reduced fees and 10 years of market exclusivity ...
Actinium to Sponsor Upcoming Blood & Marrow Transplant Information Network Webinar Focused on Stem Cell Transplants for Patients with AML
12 déc. 2016 07h00 HE
|
Actinium Pharmaceuticals
Patient focused webinar titled “Stem Cell Transplants for Acute Myeloid Leukemia: What you Need to Know” Webinar to be led by transplant expert, Dr. Patrick Stiff, Director of the Cardinal...
Actinium Highlights Results from Phase 1 Clinical Trial of Actimab-A at 58th American Society of Hematology Annual Meeting
05 déc. 2016 21h00 HE
|
Actinium Pharmaceuticals
Analysis of 2 Actimab-A Phase 1 clinical trials show that 42% of patients with low peripheral blast (PB) burden responded to Actimab-A while no patients with high PB burden responded to Actimab-AKey...
Actinium Further Strengthens Clinical Development Team with Senior Hire to Support Later-Stage Clinical Trials
29 nov. 2016 07h00 HE
|
Actinium Pharmaceuticals
NEW YORK, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload...
Actinium Issues Letter to Shareholders Highlighting 2016 Accomplishments and Anticipated Milestones for 2017
22 nov. 2016 07h00 HE
|
Actinium Pharmaceuticals
NEW YORK, Nov. 22, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...
Actinium Pharmaceuticals to Present at LD Micro Main Event Investor Conference
21 nov. 2016 07h00 HE
|
Actinium Pharmaceuticals
NEW YORK, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload...